Founded by researchers at the University of Birmingham, Binding site has continued to research, develop, manufacture and distribute specialist immunodiagnostic assays and instrumentation for over 30 years.

Binding Site has continued to build on its strong scientific foundations, supporting research and development within our field and responding to the changing needs of patients, researchers and clinicians. The company is specialised in diagnostics and produces protein tests for diagnosis of certain blood cancer diseases as well as immunological disorders. With extensive expertise in antibody specificity technology, Binding Site gives clinicians and laboratory staff the tools to significantly improve diagnosis and management of patients across a range of cancers and immune system disorders. The UK head office houses all product development, manufacturing, global distribution and marketing. Worldwide customer support is also provided by a further 10 offices in the US and Europe.

Binding Site was acquired by Nordic Capital Fund VII in 2011. Nordic Capital’s ambition is to grow the existing products through increased market penetration, especially for the main product Freelite.

Key Information

Revenues Icon

Revenues 2017*

EUR 130 million

Employees Icon

Employees

870

Ownership Icon

Ownership

Nordic Capital Fund VII, controlling shareholding

Head Office Icon

Head office

Birmingham, UK

Investment Icon

Investment date

2011

* Reported